07.19.16
Johnson & Johnson
2Q Revenues: $18.5 billion (+4%)
2Q Earnings: $4.0 billion (-12%)
YTD Revenues: $36.0 billion (+2%)
YTD Earnings: $8.5 billion (-4%)
Comments: Worldwide Pharmaceutical sales were $8.7 billion for quarter, up 9% with domestic sales up 13% and international sales up 3%. Growth was driven by newer products including IMBRUVICA (up 92% to $295 million), XARELTO (up 26% to $594 million), INVOKANA/INVOKAMET (up 20% to $383 million), and ZYTIGA (up 10% to $601 million). New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD, down 84% to $43 million due to competitive entrants. STELARA sales were $804 million, up 41%. SIMPONI/SIMPONI ARIA sales were $448 million, up 46%. REMICADE sales were $1.8 billion, up 7%. Worldwide Consumer sales were $3.4 billion for the quarter, down 2%.
2Q Revenues: $18.5 billion (+4%)
2Q Earnings: $4.0 billion (-12%)
YTD Revenues: $36.0 billion (+2%)
YTD Earnings: $8.5 billion (-4%)
Comments: Worldwide Pharmaceutical sales were $8.7 billion for quarter, up 9% with domestic sales up 13% and international sales up 3%. Growth was driven by newer products including IMBRUVICA (up 92% to $295 million), XARELTO (up 26% to $594 million), INVOKANA/INVOKAMET (up 20% to $383 million), and ZYTIGA (up 10% to $601 million). New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD, down 84% to $43 million due to competitive entrants. STELARA sales were $804 million, up 41%. SIMPONI/SIMPONI ARIA sales were $448 million, up 46%. REMICADE sales were $1.8 billion, up 7%. Worldwide Consumer sales were $3.4 billion for the quarter, down 2%.
